RxDoctor Payments Data

Brenda Tidwell

Nurse Practitioner · Hanford, CANPI 1699800383

Payments from drug & device makers

$1,974in general payments, 2019–2025

Across 82 payments — averaging $24.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$551
  • Sumitomo Pharma America, Inc.$366
  • Pfizer$207
  • Dornier Medtech America, Inc$167
  • Antares Pharma, Inc.$124
  • Axonics, Inc.$90
  • plus $470 from 11 others

What the payments were for

  • Food & beverage$1,61982%
  • Education$35518%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,974 in reported general payments places this provider in the 85th percentile of 6,779 nurse practitioner providers in California.

See all nurse practitioner providers in California

Medicare billing

Part B allowed, 2024
$43,639
Medicare patients
236
Services billed
4,609

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide43$606,075
MyrbetriqMirabegron136$112,064
Thiola EcTiopronin11$87,254
OrgovyxRelugolix13$36,082
GemtesaVibegron15$14,238
Methenamine Hippurate126$9,669
Tamsulosin Hcl356$6,266
Oxybutynin Chloride ErOxybutynin Chloride130$4,183
Solifenacin Succinate82$2,551
Finasteride154$2,123
Dutasteride82$1,876
Potassium Citrate ErPotassium Citrate14$1,740
Terazosin Hcl75$1,207
Alfuzosin Hcl ErAlfuzosin Hcl40$881
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst11$197

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$551$718,139179 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$366$50,32028 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,779 nurse practitioner providers in California.

Other nurse practitioner in Hanford

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →